8UKW

Crystal structure the extracellular region of the epidermal growth factor receptor variant III (EGFRvIII) at pH 5.0

Summary for 8UKW

• Entry DOI: 10.2210/pdb8ukw/pdb
• Related: 8UKV 8UKX
• Descriptor: Epidermal growth factor receptor, beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... (5 entities in total)
• Functional Keywords: cell surface receptor, glycoprotein, extracellular, glioblastoma, oncogenic variant, transferase
• Biological source: Homo sapiens (human); More
• Total number of polymer chains: 2
• Total formula weight: 80741.10

Authors

Stayrook, S.E.,Ferguson, K.M. (deposition date: 2023-10-15, release date: 2024-06-12, Last modification date: 2024-10-23)

Primary citation

Bagchi, A.,Stayrook, S.E.,Xenaki, K.T.,Starbird, C.A.,Doulkeridou, S.,El Khoulati, R.,Roovers, R.C.,Schmitz, K.R.,van Bergen En Henegouwen, P.M.P.,Ferguson, K.M.
Structural insights into the role and targeting of EGFRvIII.
Structure, 32:1367-, 2024

PubMed Abstract: The epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung and other cancers. In glioblastoma multiforme (GBM), the EGFR deletion variant III (EGFRvIII) is frequently found alongside EGFR amplification. Agents targeting the EGFR axis have shown limited clinical benefits in GBM and the role of EGFRvIII in GBM is poorly understood. To shed light on the role of EGFRvIII and its potential as a therapeutic target, we determined X-ray crystal structures of a monomeric EGFRvIII extracellular region (ECR). The EGFRvIII ECR resembles the unliganded conformation of EGFR, including the orientation of the C-terminal region of domain II. Domain II is mostly disordered, but the ECR structure is compact. We selected a nanobody with preferential binding to EGFRvIII relative to EGFR and structurally defined an epitope on domain IV that is occluded in the unliganded intact EGFR. These findings suggest new avenues for EGFRvIII targeting in GBM.

PubMed: 38908376
DOI: 10.1016/j.str.2024.05.018

Experimental method

X-RAY DIFFRACTION (2.39 Å)